Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Haebe, MD, Veit Bücklein, MD, Heidrun Drolle, Ulf Schoenermarck, Wolfgang Hiddemann, PhD, Michael von Bergwelt, Johanna Tischer, MD

Blood (2019) 134 (Supplement_1): 1982.

https://doi.org/10.1182/blood-2019-130685

Published: 2019

Journal Articles

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Veit Bücklein, MD, Michaela Scheurer, Bettina Brauchle, MSc, Roman Kischel, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 2632.

https://doi.org/10.1182/blood-2019-129057

Published: 2019

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Veit Bücklein, MD, Thomas Köhnke, MD, Frauke Schnorfeil, PhD, Klaus H. Metzeler, MD, Nikola P Konstandin, PhD, Annika Maria Dufour, PhD, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2018-99-119065

Published: 2018

Journal Articles

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Elena Häbe, Veit Bücklein, MD, Christoph Schulz, MD, Heidrun Drolle, Susanne Fritsch, Georg Ledderose, Michael von Bergwelt, MD, Wolfgang Hiddemann, PhD, Johanna Tischer

Blood (2018) 132 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2018-99-119103

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Veit Bücklein, MD, Thomas Koehnke, MD, Sandra Rechkemmer, Frauke Schnorfeil, PhD, Stephanie Schneider, PhD, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Cristina Sauerland, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 5081.

https://doi.org/10.1182/blood.V130.Suppl_1.5081.5081

Published: 2017

Journal Articles

Proposal For a Novel Scoring System For The Diagnosis Of CLL

Thomas Köhnke, MD, Veronika K Wittmann, Daniela Sauter, MD, Veit Bücklein, MD, Zlatana Pasalic, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2013) 122 (21): 4150.

https://doi.org/10.1182/blood.V122.21.4150.4150

Published: 2013

NARROW

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Proposal For a Novel Scoring System For The Diagnosis Of CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only